Industry Briefs: July 9, 2012 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Industry Briefs: July 9, 2012
A roundup of additional company and people news from pharmaceutical and biopharmaceutical companies, their suppliers, and contract-service providers.


Company News

AstraZeneca has completed the previously announced sale of the assets of its subsidiary, Aptium Oncology. Read More

Cancer Research Technology (CRT), the commercial arm of Cancer Research UK, and ADC Therapeutics Sarl (ADCT) have signed agreements to develop antibody drug conjugates using CRT’s antibodies and peptides, and ADCT’s linker chemistries and proprietary pyrrolobenzodiazepines technology. Read More

The CureBeta R&D collaboration between Evotec and Harvard University has entered into a strategic alliance with Janssen Pharmaceuticals. Read More

Hal Allergy has expanded its GMP contract manufacturing activities for clinical-batch supply of both recombinant and viral products. Read More

Prokarium, a spin-out company of Cobra Biologics, has acquired oral-vaccine technology from Emergent BioSolutions. Read More

Sanofi has agreed to divest its 19.3% stake in the Yves Rocher Group. Read More

Spectrum Pharmaceuticals has provided an additional extension of the offer period in connection with its tender offer to purchase all of the outstanding shares of common stock of Allos Therapeutics for $1.82 per share in cash. Read More

People News

Affymax has named Michael Holfinger vice-president of manufacturing and CMC development. Read More

Arena Pharmaceuticals has appointed Craig M. Audet to executive officer as senior vice-president, operations, and head of global regulatory affairs. Read More

Chiral Technologies has appointed Jauh-Tzuoh Lee as technology manager. Read More

Ricerca Biosciences named G. Lynn Miesel technical director. Read More

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
26%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
10%
All of the above.
43%
No government involvement in patient treatment or drug development.
10%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?

Click here